As young children, twins Eric and Evan Edwards were diagnosed with life-threatening allergies to a wide range of items, including peanuts, tree nuts, seafood and eggs. Eric and Evan were supposed to have a dose of potentially life-saving epinephrine close at all times. Over time, however, they became increasingly frustrated that the epinephrine delivery systems available were not designed with users like them in mind. In the twins’ opinion, the devices were awkward to carry and difficult to use.
In their late teens, Eric and Evan decided to develop a better solution for people just like themselves They conceived of a new epinephrine delivery system that was truly “developed by patients, for patients®.” They shaped their education to provide the skills needed, and together with their family and some initial financial supporters, they formed a company to make this a reality; and so Intelliject was born.
In due course, it became apparent that Intelliject’s technology platforms had the potential to significantly improve treatment options for patients in other therapy areas as well. In every therapy area, however, the Intelliject goal is the same: to develop drug/device combination products that provide better solutions than are currently available, together with appropriate supporting data.
Eric and Evan have developed deep expertise in drug and device design and development and remain key members of Intelliject’s management team. In the meantime, they have been joined by a group of industry executives with many years of experience and track records of success in medical devices and pharmaceuticals. This management team all share a passion for putting the patient at the center of all that they do, and harnessing innovation to produce demonstrably superior healthcare solutions.